Columnist Alliah Czarielle offers insight into how obesity and fat-shaming can affect people with hemophilia, particularly young folks.

The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.

Females can also be affected but tend to have milder symptoms. People with mild hemophilia A may have prolonged bleeding events after a surgical procedure, dental work, or a serious injury.

Like any other disease, hemophilia also has its signs and symptoms. Hemophilia symptoms may present for the first time during any scheduled surgery. • Excessive external bleeding that may first ...

The U.S. Food and Drug Administration (FDA) approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce ...

Pfizer Inc. has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without inhibitors — making it the first antitissue-factor pathway inhibitor to be allowed for ...

Researchers reviewed data from 14 hemophilia patients treated with Sevenfact to better understand its real-world safety and ...

Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...

Marstacimab is a human monoclonal immunoglobulin G type 1 antibody that enhances coagulation by targeting the Kunitz 2 domain of tissue factor pathway inhibitor.

The Food and Drug Administration approved Pfizer’sPFE-0.17%decrease; red down pointing triangle Hympavzi to prevent or reduce bleeding episodes in patients with certain kinds of hemophilia ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ ...

Pfizer Inc. (PFE) announced Friday that the U.S. Food and Drug Administration has approved HYMPAVZI (marstacimab-hncq) for routine ...